Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 3, 1998, Pages 721-726

  Clarkson, Thomas B ^a   Anthony, Mary S ^a   Jerome, Christopher P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BONE MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIETARY INTAKE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; LIPID BLOOD LEVEL; MONKEY; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIET, ATHEROGENIC; ESTRADIOL; ESTROGENS; FEMALE; HORSES; LIPIDS; LIPOPROTEINS; MACACA FASCICULARIS; OSMOLAR CONCENTRATION; OVARIECTOMY; PIPERIDINES; POSTMENOPAUSE; RALOXIFENE;

ANIMALIA; EQUIDAE; MACACA FASCICULARIS;

EID: 0031733090     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.3.721     Document Type: Article

References (28)

1. Stampfer MJ, Colditz GA. 1991 Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:47-63.
2. Grady D, Rubin SM, Petitti DB, et al. 1992 Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1016-1037.
3. Lindsay R. 1993 Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med. 95(Suppl 5A):37-39.
4. Paganini-Hill A. 1996 Oestrogen replacement therapy and Alzheimer's disease. Br J Obstet Gynaecol. 103(Suppl 13):80-86.
5. Colditz GA, Hankinson SE, Hunter DJ, et al. 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1589-1593.
6. Hulka BS. 1994 Links between hormone replacement therapy and neoplasia. Fertil Steril. 62(Suppl 2):168S-175S.
7. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. 1995 Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 85:304-313.
8. Persson I, Yuen J, Bergkvist L, Schairer C. 1996 Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 67:327-332.
9. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. 1997 Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 17:217-221.
10. Bush TL, Cowan LD, Barrett-Connor E, et al. 1983 Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics program follow-up study. JAMA. 249:903-906.
11. Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. 1993 Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol. 137:1125-1135.
12. Hemminski E, Brambilla BDJ, McKinlay SM, Posner JG. 1991 Use of estrogens among middle-aged Massachusetts women. Ann Pharmacother. 25:418-422.
13. Nabulsi AA, Folsom AR, White A, for the ARIC Investigators. 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 328:1069-1075.
14. Fuchs-Young R, Glasebrook AL, Short LL, et al. 1995 Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci. 630:355-360.
15. Black LJ, Sato M, Rowley ER, et al. 1994 Raloxifene (LY 139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:63-69.
16. Sato M, Bryant HU, Iversen P, et al. 1995 Advantages of raloxifene over alendronate or estrogen on nonreproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther. 279:298-305.
17. Sato M, Rippy MK, Bryant HU. 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:905-912.
18. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. 1974 Enzymatic determination of total serum cholesterol. Clin Chem. 20:470-475.
19. Lipid Research Clinics Program. 1984 Manual of laboratory operations: lipid and lipoprotein analysis. Bethesda: National Institutes of Health; DHEW Publication 75-628 (revised).
20. Wilson ME, Gordon TP, Rudman CG, Tanner JM. 1988 Effects of a natural vs. artificial environment on the tempo of maturation in female rhesus monkeys. Endocrinology. 123:2653-2661.
21. Clarkson TB. 1984 Progression and regression of nonhuman primate coronary artery atherosclerosis: considerations of experimental design. In: Malinow MR, Blaton VH, eds. Regression of atherosclerotic lesions. New York: Plenum Press; 43-60.
22. Williams JK, Anthony MS, Honoré EK, et al. 1995 Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 15:827-836.
23. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. 1996 A controlled trial of raloxifene (LY139481) HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:835-842.
24. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1222-1225.
25. Adams MR, Kaplan JR, Manuck SB, et al. 1990 Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 10:1051-1057.
26. Englund DE, Johansson EDB. 1978 Plasma levels of oestrone, oestradiol and gonadotrophins in postmenopausal women after oral and vaginal administration of conjugated equine estrogens (Premarin). Br J Obstet Gynaecol. 85:957-964.
27. Adams MR, Kaplan JR, Koritnik DR, Clarkson TB. 1985 Ovariectomy, social status, and atherosclerosis in cynomolgus monkeys. Arteriosclerosis. 5:192-200.
28. Jerome CP, Lees CJ. 1996 Raloxifene increases bone mass and reduces bone turnover in ovariectomized cynomolgus monkeys [Abstract]. J Bone Miner. 11(Suppl 1):S445.